Kate Gifford 
The MiSight 1 day clinical trial is the longest-running soft contact lens study among children, and is now reporting seven-year data. With questions explored including efficacy, cross over from control group to treatment and discontinuation, here’s some of what we’ve learnt along the way.
In this Q&A Interview, Optometrist Elizabeth Lumb reflects on the evolution of myopia management in the past five years through two ‘lenses’: as CooperVision’s Director of Global Professional Affairs, Myopia Management, and through the very personal experience of her now 12-year-old niece, Maddy.
Orthokeratology fitting to children is increasing in frequency worldwide, due to its volume of evidence for myopia control. Learn what data inputs are needed and how to best use your topographer for accurate ortho-k lens design.
The SightGlass DOT 0.2 lens presents a new theory in myopia control, with clinical trial evidence of efficacy in children from 6 to 10 years of age. Diffusion Optics Technology (DOT) incorporates microdots to modulate retinal contrast; it does not employ defocus as for other optical treatments. Learn more here.
The contrast theory in myopia development and control is based on links between retinal cone expressions, genetics and myopia. This is distinct from peripheral defocus and simultaneous defocus theories and underpins the new SightGlass DOT 0.2 spectacle lens for myopia control. Learn more here.
Digital eye strain is becoming more common in children and teenagers. The symptoms of asthenopia can be due to dry eye, binocular vision dysfunction and glare sensitivity – learn more about each of these, as well as guidelines to manage the risks.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
Extended depth of focus (EDOF) designs in soft contact lenses are employed for presbyopia correction as well as myopia control. This article explores differences between contact lens designs which could be termed ‘multifocal’, and how this could factor into clinical outcomes.
Spectacle lenses which effectively control myopia progression are the next phase in widespread uptake of myopia management. Learn more about the Essilor Stellest lens, from myopia control to vision and visual function outcomes.
Two prototype myopia control soft contact lens designs with non-coaxial optics showed enhanced efficacy in one design and enhanced vision in the other, compared to dual-focus and single-vision designs. This initial data is for six months, and all myopia control contact lens designs showed close to 6/6 or 20/20 acuity equivalent.
